NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Phase 1

Active, not recruiting

Conditions: Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
Aggressive B-cell Lymphoma With Secondary Involvement of the CNS

Interventions: Drug: Obinutuzumab
Drug: Prednisone
Drug: Lenalidomide
Drug: Venetoclax
Drug: Ibrutinib
Drug: Acetaminophen
Drug: Diphenhydramine
Other: Peg-filgrastim
Diagnostic Test: CT Scan (chest, abdomen, and pelvis)
Diagnostic Test: MRI
Diagnostic Test: 18f-FDG-PET
Diagnostic Test: PET
Diagnostic Test: Lumbar puncture/Ommaya tap
Diagnostic Test: Bone marrow aspiration/biopsy
Combination Product: EKG

First Posted Date: 2022-01-27

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT05211336

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body

Phase 1

Terminated

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Triple-Negative Breast Inflammatory Carcinoma

Interventions: Drug: Dasatinib
Dietary Supplement: Icosapent Ethyl

First Posted Date: 2022-01-20

Last Posted Date: 2024-01-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT05198843

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Stage III Lung Cancer AJCC v8
Lung Adenocarcinoma
Lung Large Cell Carcinoma
Lung Non-Squamous Non-Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Biological: Durvalumab
Procedure: FDG-Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Drug: Methoxyamine
Drug: Pemetrexed
Radiation: Radiation Therapy

First Posted Date: 2022-01-20

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT05198830

Locations: 🇺🇸
Keck Medicine of USC Buena Park, Buena Park, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States

and more 24 locations

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Phase 2

Active, not recruiting

Conditions: Gynecologic Cancer
Gynecologic Neoplasms
Peritoneal Carcinomatosis
Peritoneal Neoplasms
Ovarian Cancer
Ovarian Neoplasms
Colorectal Cancer
Colorectal Neoplasms
Appendiceal Cancer
Appendiceal Neoplasms

Interventions: Drug: Paclitaxel
Drug: Nilotinib

First Posted Date: 2022-01-11

Last Posted Date: 2025-03-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT05185947

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Phase 1

Recruiting

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Head and Neck Carcinoma of Unknown Primary
Locally Advanced Head and Neck Squamous Cell Carcinoma
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Locally Advanced Laryngeal Squamous Cell Carcinoma
Locally Advanced Nasal Cavity Squamous Cell Carcinoma
Locally Advanced Oral Cavity Squamous Cell Carcinoma
Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Locally Advanced Paranasal Sinus Squamous Cell Carcinoma
Locally Advanced Sinonasal Squamous Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Biopsy Procedure
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Ipatasertib
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy

First Posted Date: 2021-12-29

Last Posted Date: 2025-04-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT05172245

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Kansas Clinical Research Center, Fairway, Kansas, United States

and more 15 locations

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Phase 2

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Metastatic Oral Cavity Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Metastatic Hypopharyngeal Squamous Cell Carcinoma
Metastatic Laryngeal Squamous Cell Carcinoma
Metastatic Oropharyngeal Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Squamous Cell Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ipatasertib
Biological: Pembrolizumab

First Posted Date: 2021-12-29

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT05172258

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States

and more 17 locations

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2

Recruiting

Conditions: Advanced Locoregional Melanoma
Metastatic Melanoma
Metastatic Renal Cell Carcinoma
Clear Cell Histology

Interventions: Drug: Pembrolizumab
Drug: Aldesleukin

First Posted Date: 2021-12-13

Last Posted Date: 2025-02-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT05155033

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

Phase 2

Recruiting

Conditions: Localized Prostate Cancer

Interventions: Drug: 18F-DCFPyL

First Posted Date: 2021-12-13

Last Posted Date: 2025-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT05155046

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

BMS-986253 in Myelodysplastic Syndromes

Phase 1

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine
Drug: BMS-986253
Procedure: Bone Marrow Biopsy
Drug: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine
Procedure: ECG
Procedure: Bone Marrow Aspiration

First Posted Date: 2021-12-08

Last Posted Date: 2025-04-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT05148234

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia Post Cytotoxic Therapy
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Recurrent Myelodysplastic Syndrome
Refractory Mixed Phenotype Acute Leukemia
Down Syndrome
Myelodysplastic Syndrome Post Cytotoxic Therapy
Recurrent Mixed Phenotype Acute Leukemia

Interventions: Drug: Cytarabine
Drug: Fludarabine
Drug: Leucovorin
Drug: Triple Intrathecal Chemotherapy
Drug: Uproleselan

First Posted Date: 2021-12-07

Last Posted Date: 2025-05-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT05146739

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 16 locations

Home Terms & Conditions Privacy Policy